We believe Optina represents a potential blockbuster drug for Ampio pharmaceuticals.
Diabetic macular edema (DME) is one of the leading cause of blindness in adults. The current treatments for DME include focal laser photocoagulation, intravitreal injection of steroids (kenalog and triescence). In recalcitrant cases even surgical vitrectomy is offered. The medical burden of this disease is enormous both for patients and the health care system. The treatment of laser photocoagulation for one eye with DME costs several hundred dollars and it is primarily for prevention of vision loss. When edema is close to the fovea then laser may not be an option and the eye is injected with medications that have risks of infection, retinal detachment and inflammation to name a few.
Having another option in the treatment of this very common problem would be welcome by primary care physicians, ophthalmologists, retina specialists, etc. If Optina is approved it will be a blockbuster - a noninvasive and safe method to decrease macular edema and preserve sight. People who see better - live longer and are happier and less likely to fall and develop other complications such as hip fractures which has a high 5 year mortality.
We believe this safe medication with apparent different actions at different dosages will be an exciting one to watch.